Aclaris Therapeutics, Inc. ACRS
Analyst Ratings
- Consensus
- Buy — 7 Buy · 0 Hold · 0 Sell (7 analysts)
- Avg. Price Target
- $11.71 (+216.6% upside)
Key Stats
- Today's Range
- $3.65 – $4.24
- 50-Day Range
- $3.65 – $6.60
- 52-Week Range
- $1.74 – $6.60
- Volume
- 3.53 million shs
- Average Volume
- 2.94 million shs
- Market Cap
- $628.54 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 2.38%
- Days to Cover
- 9.95
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Related Stocks
Compare head-to-head: ACRS vs LLY·ACRS vs JNJ·ACRS vs ABBV·ACRS vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.